EGFR inhibition adds toxicity, no benefit in head & neck cancer

Adding the investigational EGFR antibody zalutumumab (Genmab A/S) to primary  chemoradiotherapy did not improve outcome in patients with head and neck squamous cell carcinoma, according to the results of the phase III Danish Head and Neck Cancer Group (DAHANCA)-19 trial.

MedScape